Emerging Role of Ferroptosis in Diabetes and Associated Complications: When Metabolic Dysregulation Meets Cell Death

Abstract

Diabetes mellitus (DM) is a metabolic disorder marked by persistent hyperglycemia (HG), resulting from abnormalities in insulin secretion or insulin resistance. This condition represents a major public health concern since it causes multisystem complications, including microvascular diseases, macrovascular diseases, and neuropathy. Few effective therapies are currently available. Ferroptosis, an iron-dependent mode of regulated cell death triggered by lipid peroxidation (LPO), is intricately linked to the pathogenesis, progression, and complications of DM. It has been increasingly recognised as a key mechanism underlying peripheral insulin resistance and insulin deficiency resulting from β-cell dysfunction. In this study, we systematically summarised the primary regulatory mechanisms of ferroptosis and outlined current research advancements in mechanistic insights into its role in diabetic complications. Besides, we explored how inter-organelle interactions drive ferroptosis under diabetic conditions and play pathogenic effects in diabetes and its complications. Finally, we systematically reviewed the therapeutic drugs targeting ferroptosis from the perspectives of traditional Chinese medicine (TCM) and Western medicine, respectively. This interdisciplinary integrated overview may provide a theoretical basis for future clinical transformation.

Keywords

diabetes mellitus (DM) / diabetic complications / ferroptosis / molecular mechanisms / research progress

References

[1] D. J. Magliano, E. J. Boyko, and IDF Diabetes Atlas 10th Edition Scientific Committee, IDF Diabetes Atlas (International Diabetes Federation International Diabetes Federation, 2021).

[2] American Diabetes Association, “Classification and Diagnosis of Diabetes,” Diabetes Care 38, no. Suppl (2015): S8–S16.

[3] V. Rigalleau, Y. Pucheux, T. Couffinhal, et al., “Skin Autofluorescence of Advanced Glycation End-Products, Glycemic Memory, and Diabetes Complications,” Diabetes & Metabolism 51, no. 1 (2025): 101600.

[4] S. J. Dixon, K. M. Lemberg, M. R. Lamprecht, et al., “Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death,” Cell 149, no. 5 (2012): 1060–1072.

[5] E. Park and S. W. Chung, “ROS-Mediated Autophagy Increases Intracellular Iron Levels and Ferroptosis by Ferritin and Transferrin Receptor Regulation,” Cell Death & Disease 10, no. 11 (2019): 822.

[6] H. F. Yan, T. Zou, Q. Z. Tuo, et al., “Ferroptosis: Mechanisms and Links With Diseases,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 49.

[7] J. He, Z. Li, P. Xia, et al., “Ferroptosis and Ferritinophagy in Diabetes Complications,” Molecular Metabolism 60 (2022): 101470.

[8] B. J. Crielaard, T. Lammers, and S. Rivella, “Targeting Iron Metabolism in Drug Discovery and Delivery,” Nature Reviews. Drug Discovery 16, no. 6 (2017): 400–423.

[9] J. Li, F. Cao, H. L. Yin, et al., “Ferroptosis: Past, Present and Future,” Cell Death & Disease 11, no. 2 (2020): 88.

[10] E. Nemeth, M. S. Tuttle, J. Powelson, et al., “Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization,” Science 306, no. 5704 (2004): 2090–2093.

[11] H. Gunshin, B. Mackenzie, U. V. Berger, et al., “Cloning and Characterization of a Mammalian Proton-Coupled Metal-Ion Transporter,” Nature 388, no. 6641 (1997): 482–488.

[12] N. Gattermann, M. U. Muckenthaler, A. E. Kulozik, G. Metzgeroth, and J. Hastka, “The Evaluation of Iron Deficiency and Iron Overload,” Deutsches Ärzteblatt International 118, no. 49 (2021): 847–856.

[13] C. C. Hsu, N. H. Senussi, K. Y. Fertrin, and K. V. Kowdley, “Iron overload disorders,” Hepatology Communications 6, no. 8 (2022): 1842–1854.

[14] P. Liu, Z. Zhang, Y. Cai, Z. Li, Q. Zhou, and Q. Chen, “Ferroptosis: Mechanisms and Role in Diabetes Mellitus and Its Complications,” Ageing Research Reviews 94 (2024): 102201.

[15] H. Gao, Z. Jin, G. Bandyopadhyay, et al., “Aberrant Iron Distribution via Hepatocyte-Stellate Cell Axis Drives Liver Lipogenesis and Fibrosis,” Cell Metabolism 34, no. 8 (2022): 1201–1213.e1205.

[16] S. Kumfu, J. Sripetchwandee, C. Thonusin, et al., “Ferroptosis Inhibitor Improves Cardiac Function More Effectively Than Inhibitors of Apoptosis and Necroptosis Through Cardiac Mitochondrial Protection in Rats With Iron-Overloaded Cardiomyopathy,” Toxicology and Applied Pharmacology 479 (2023): 116727.

[17] S. A. Mousavi-Aghdas, E. Farashi, and N. Naderi, “Iron Dyshomeostasis and Mitochondrial Function in the Failing Heart: A Review of the Literature,” American Journal of Cardiovascular Drugs 24, no. 1 (2024): 19–37.

[18] D. Devos, Z. I. Cabantchik, C. Moreau, et al., “Conservative Iron Chelation for Neurodegenerative Diseases Such as Parkinson's Disease and Amyotrophic Lateral Sclerosis,” Journal of Neural Transmission 127, no. 2 (2020): 189–203.

[19] L. Qu, X. He, Q. Tang, X. Fan, J. Liu, and A. Lin, “Iron Metabolism, Ferroptosis, and lncRNA in Cancer: Knowns and Unknowns,” Journal of Zhejiang University. Science. B 23, no. 10 (2022): 844–862.

[20] Y. Chen, X. Li, S. Wang, R. Miao, and J. Zhong, “Targeting Iron Metabolism and Ferroptosis as Novel Therapeutic Approaches in Cardiovascular Diseases,” Nutrients 15, no. 3 (2023): 591.

[21] D. Tang, X. Chen, R. Kang, and G. Kroemer, “Ferroptosis: Molecular Mechanisms and Health Implications,” Cell Research 31, no. 2 (2021): 107–125.

[22] G. Minotti and S. D. Aust, “The Role of Iron in Oxygen Radical Mediated Lipid Peroxidation,” Chemico-Biological Interactions 71, no. 1 (1989): 1–19.

[23] H. Feng and B. R. Stockwell, “Unsolved Mysteries: How Does Lipid Peroxidation Cause Ferroptosis?,” PLoS Biology 16, no. 5 (2018): e2006203.

[24] S. Sun, J. Shen, J. Jiang, F. Wang, and J. Min, “Targeting Ferroptosis Opens New Avenues for the Development of Novel Therapeutics,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 372.

[25] E. Soupene, H. Fyrst, and F. A. Kuypers, “Mammalian Acyl-CoA:Lysophosphatidylcholine Acyltransferase Enzymes,” Proceedings of the National Academy of Sciences of the United States of America 105, no. 1 (2008): 88–93.

[26] Q. Ru, Y. Li, L. Chen, Y. Wu, J. Min, and F. Wang, “Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 271.

[27] B. R. Stockwell, J. P. Friedmann Angeli, H. Bayir, et al., “Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease,” Cell 171, no. 2 (2017): 273–285.

[28] W. S. Yang, R. SriRamaratnam, M. E. Welsch, et al., “Regulation of Ferroptotic Cancer Cell Death by GPX4,” Cell 156, no. 1–2 (2014): 317–331.

[29] J. J. Chen and L. Galluzzi, “Fighting Resilient Cancers With Iron,” Trends in Cell Biology 28, no. 2 (2018): 77–78.

[30] X. Jiang, B. R. Stockwell, and M. Conrad, “Ferroptosis: Mechanisms, Biology and Role in Disease,” Nature Reviews. Molecular Cell Biology 22, no. 4 (2021): 266–282.

[31] H. Imai, M. Matsuoka, T. Kumagai, T. Sakamoto, and T. Koumura, “Lipid Peroxidation-Dependent Cell Death Regulated by GPx4 and Ferroptosis,” Current Topics in Microbiology and Immunology 403 (2017): 143–170.

[32] G. C. Forcina and S. J. Dixon, “GPX4 at the Crossroads of Lipid Homeostasis and Ferroptosis,” Proteomics 19, no. 18 (2019): e1800311.

[33] G. J. McBean, “The Transsulfuration Pathway: A Source of Cysteine for Glutathione in Astrocytes,” Amino Acids 42, no. 1 (2012): 199–205.

[34] M. Gao, P. Monian, N. Quadri, R. Ramasamy, and X. Jiang, “Glutaminolysis and Transferrin Regulate Ferroptosis,” Molecular Cell 59, no. 2 (2015): 298–308.

[35] S. Doll, B. Proneth, Y. Y. Tyurina, et al., “ACSL4 Dictates Ferroptosis Sensitivity by Shaping Cellular Lipid Composition,” Nature Chemical Biology 13, no. 1 (2017): 91–98.

[36] J. Guo, L. Chen, and M. Ma, “Ginsenoside Rg1 Suppresses Ferroptosis of Renal Tubular Epithelial Cells in Sepsis-Induced Acute Kidney Injury via the FSP1-CoQ(10)-NAD(P)H Pathway,” Current Medicinal Chemistry 31, no. 15 (2024): 2119–2132.

[37] D. Wang, W. Liang, D. Huo, et al., “SPY1 Inhibits Neuronal Ferroptosis in Amyotrophic Lateral Sclerosis by Reducing Lipid Peroxidation Through Regulation of GCH1 and TFR1,” Cell Death and Differentiation 30, no. 2 (2023): 369–382.

[38] C. Mao, X. Liu, Y. Zhang, et al., “DHODH-Mediated Ferroptosis Defence Is a Targetable Vulnerability in Cancer,” Nature 593, no. 7860 (2021): 586–590.

[39] J. T. Madak, A. Bankhead, C. R. Cuthbertson, H. D. Showalter, and N. Neamati, “Revisiting the Role of Dihydroorotate Dehydrogenase as a Therapeutic Target for Cancer,” Pharmacology & Therapeutics 195 (2019): 111–131.

[40] D. Liang, Y. Feng, F. Zandkarimi, et al., “Ferroptosis Surveillance Independent of GPX4 and Differentially Regulated by Sex Hormones,” Cell 186, no. 13 (2023): 2748–2764.e2722.

[41] Y. Yang, Y. Ma, Q. Li, et al., “STAT6 Inhibits Ferroptosis and Alleviates Acute Lung Injury via Regulating P53/SLC7A11 Pathway,” Cell Death & Disease 13, no. 6 (2022): 530.

[42] Y. Yang, J. Ren, J. Zhang, H. Shi, J. Wang, and Y. Yan, “FTO Ameliorates Doxorubicin-Induced Cardiotoxicity by Inhibiting Ferroptosis via P53-P21/Nrf2 Activation in a HuR-Dependent m6A Manner,” Redox Biology 70 (2024): 103067.

[43] B. Niu, X. Lei, Q. Xu, et al., “Protecting Mitochondria via Inhibiting VDAC1 Oligomerization Alleviates Ferroptosis in Acetaminophen-Induced Acute Liver Injury,” Cell Biology and Toxicology 38, no. 3 (2022): 505–530.

[44] R. P. Saneto and F. A. Perez, “Mitochondria-Associated Membrane Scaffolding With Endoplasmic Reticulum: A Dynamic Pathway of Developmental Disease,” Frontiers in Molecular Biosciences 9 (2022): 908721.

[45] H. Liu, S. Zheng, G. Hou, et al., “AKAP1/PKA-Mediated GRP75 Phosphorylation at Mitochondria-Associated Endoplasmic Reticulum Membranes Protects Cancer Cells Against Ferroptosis,” Cell Death and Differentiation 32, no. 3 (2025): 488–505.

[46] S. T. Degechisa, Y. T. Dabi, and S. T. Gizaw, “The Mitochondrial Associated Endoplasmic Reticulum Membranes: A Platform for the Pathogenesis of Inflammation-Mediated Metabolic Diseases,” Immunity, Inflammation and Disease 10, no. 7 (2022): e647.

[47] J. Chen, D. Liu, L. Lei, et al., “CNPY2 Aggravates Renal Tubular Cell Ferroptosis in Diabetic Nephropathy by Regulating PERK/ATF4/CHAC1 Pathway and MAM Integrity,” Advanced Science 12, no. 25 (2025): e2416441.

[48] S. Wu, Q. Lu, Y. Ding, et al., “Hyperglycemia-Driven Inhibition of AMP-Activated Protein Kinase α2 Induces Diabetic Cardiomyopathy by Promoting Mitochondria-Associated Endoplasmic Reticulum Membranes In Vivo,” Circulation 139, no. 16 (2019): 1913–1936.

[49] M. Xu, S. Zhong, N. Zhu, et al., “Oxidative and Endoplasmic Reticulum Stress in Diabetes-Related Hearing Loss: Protective Effects of Thioredoxin,” Life Sciences 359 (2024): 123223.

[50] L. Deng, M. Q. Mo, J. Zhong, Z. Li, G. Li, and Y. Liang, “Iron Overload Induces Islet β Cell Ferroptosis by Activating ASK1/P-P38/CHOP Signaling Pathway,” PeerJ 11 (2023): e15206.

[51] Y. Zhao, H. Guo, Q. Li, et al., “TREM1 Induces Microglial Ferroptosis Through the PERK Pathway in Diabetic-Associated Cognitive Impairment,” Experimental Neurology 383 (2025): 115031.

[52] X. Zhang, L. Jiang, H. Chen, et al., “Resveratrol Protected Acrolein-Induced Ferroptosis and Insulin Secretion Dysfunction via ER-Stress-Related PERK Pathway in MIN6 Cells,” Toxicology 465 (2022): 153048.

[53] D. J. Peña-Montes, M. Huerta-Cervantes, H. Riveros-Rosas, et al., “Iron Chelation Mitigates Mitochondrial Dysfunction and Oxidative Stress by Enhancing nrf2-Mediated Antioxidant Responses in the Renal Cortex of a Murine Model of Type 2 Diabetes,” Mitochondrion 78 (2024): 101937.

[54] W. Tang, Y. Li, S. He, et al., “Caveolin-1 Alleviates Diabetes-Associated Cognitive Dysfunction Through Modulating Neuronal Ferroptosis-Mediated Mitochondrial Homeostasis,” Antioxidants & Redox Signaling 37, no. 13–15 (2022): 867–886.

[55] Q. Li, J. Liao, W. Chen, et al., “NAC Alleviative Ferroptosis in Diabetic Nephropathy via Maintaining Mitochondrial Redox Homeostasis Through Activating SIRT3-SOD2/Gpx4 Pathway,” Free Radical Biology & Medicine 187 (2022): 158–170.

[56] Y. Do, M. Yagi, H. Hirai, et al., “Cardiomyocyte-Specific Deletion of the Mitochondrial Transporter Abcb10 Causes Cardiac Dysfunction via Lysosomal-Mediated Ferroptosis,” Bioscience Reports 44, no. 5 (2024): BSR20231992.

[57] C. Arden, S. H. Park, X. R. Yasasilka, E. Y. Lee, and M. S. Lee, “Autophagy and Lysosomal Dysfunction in Diabetes and Its Complications,” Trends in Endocrinology and Metabolism 35, no. 12 (2024): 1078–1090.

[58] C. Liu, W. Sun, T. Zhu, et al., “Glia Maturation Factor-β Induces Ferroptosis by Impairing Chaperone-Mediated Autophagic Degradation of ACSL4 in Early Diabetic Retinopathy,” Redox Biology 52 (2022): 102292.

[59] X. Shao, X. Ren, T. Xing, et al., “Time Series Imaging the Mitochondrial Microenvironment and Its Interactions With Lysosomes During Ferroptosis,” Analytical Chemistry 97, no. 11 (2025): 6155–6162.

[60] A. Bezawork-Geleta, J. Dimou, and M. J. Watt, “Lipid Droplets and Ferroptosis as New Players in Brain Cancer Glioblastoma Progression and Therapeutic Resistance,” Frontiers in Oncology 12 (2022): 1085034.

[61] M. Yang, S. Luo, J. Yang, et al., “Lipid Droplet - Mitochondria Coupling: A Novel Lipid Metabolism Regulatory Hub in Diabetic Nephropathy,” Frontiers in Endocrinology 13 (2022): 1017387.

[62] H. Fan and Y. Tan, “Lipid Droplet-Mitochondria Contacts in Health and Disease,” International Journal of Molecular Sciences 25, no. 13 (2024): 6878.

[63] Y. Jin, Y. Tan, L. Chen, Y. Liu, and Z. Ren, “Reactive Oxygen Species Induces Lipid Droplet Accumulation in HepG2 Cells by Increasing Perilipin 2 Expression,” International Journal of Molecular Sciences 19, no. 11 (2018): 3445.

[64] H. T. Endale, W. Tesfaye, and T. A. Mengstie, “ROS Induced Lipid Peroxidation and Their Role in Ferroptosis,” Frontiers in Cell and Developmental Biology 11 (2023): 1226044.

[65] Q. Wu, M. Zhao, X. He, et al., “Acetylcholine Reduces Palmitate-Induced Cardiomyocyte Apoptosis by Promoting Lipid Droplet Lipolysis and Perilipin 5-Mediated Lipid Droplet-Mitochondria Interaction,” Cell Cycle 20, no. 18 (2021): 1890–1906.

[66] M. Yang, C. Liu, N. Jiang, et al., “Sesamol Ameliorates Lipid Deposition by Maintaining the Integrity of the Lipid Droplet-Mitochondria Connection in Diabetic Nephropathy,” Journal of Agricultural and Food Chemistry 73, no. 3 (2025): 2124–2137.

[67] S. Dai, J. Long, W. Han, L. Zhang, and B. Chen, “Alleviative Effect of Probiotics and Prebiotics on Dry Eye in Type 2 Diabetic Mice Through the Gut-Eye Axis,” Ocular Surface 36 (2025): 244–260.

[68] Z. Zhang, J. Tang, J. Song, et al., “Elabela Alleviates Ferroptosis, Myocardial Remodeling, Fibrosis and Heart Dysfunction in Hypertensive Mice by Modulating the IL-6/STAT3/GPX4 Signaling,” Free Radical Biology & Medicine 181 (2022): 130–142.

[69] L. Deng, S. He, N. Guo, W. Tian, W. Zhang, and L. Luo, “Molecular Mechanisms of Ferroptosis and Relevance to Inflammation,” Inflammation Research 72, no. 2 (2023): 281–299.

[70] E. F. Luo, H. X. Li, Y. H. Qin, et al., “Role of Ferroptosis in the Process of Diabetes-Induced Endothelial Dysfunction,” World Journal of Diabetes 12, no. 2 (2021): 124–137.

[71] E. Aigner, T. K. Felder, H. Oberkofler, et al., “Glucose Acts as a Regulator of Serum Iron by Increasing Serum Hepcidin Concentrations,” Journal of Nutritional Biochemistry 24, no. 1 (2013): 112–117.

[72] C. A. Robson-Doucette, S. Sultan, E. M. Allister, et al., “Beta-Cell Uncoupling Protein 2 Regulates Reactive Oxygen Species Production, Which Influences Both Insulin and Glucagon Secretion,” Diabetes 60, no. 11 (2011): 2710–2719.

[73] M. Santos, C. P. Anderson, S. Neschen, et al., “Irp2 Regulates Insulin Production Through Iron-Mediated Cdkal1-Catalyzed tRNA Modification,” Nature Communications 11, no. 1 (2020): 296.

[74] J. Huang, D. Jones, B. Luo, et al., “Iron Overload and Diabetes Risk: A Shift From Glucose to Fatty Acid Oxidation and Increased Hepatic Glucose Production in a Mouse Model of Hereditary Hemochromatosis,” Diabetes 60, no. 1 (2011): 80–87.

[75] G. Medina-Gómez, “Mitochondria and Endocrine Function of Adipose Tissue,” Best Practice & Research. Clinical Endocrinology & Metabolism 26, no. 6 (2012): 791–804.

[76] S. Elumalai, U. Karunakaran, J. S. Moon, and K. C. Won, “Ferroptosis Signaling in Pancreatic β-Cells: Novel Insights & Therapeutic Targeting,” International Journal of Molecular Sciences 23, no. 22 (2022): 13679.

[77] E. S. Eshak, H. Iso, K. Maruyama, I. Muraki, and A. Tamakoshi, “Associations Between Dietary Intakes of Iron, Copper and Zinc With Risk of Type 2 Diabetes Mellitus: A Large Population-Based Prospective Cohort Study,” Clinical Nutrition 37, no. 2 (2018): 667–674.

[78] S. Lenzen, J. Drinkgern, and M. Tiedge, “Low Antioxidant Enzyme Gene Expression in Pancreatic Islets Compared With Various Other Mouse Tissues,” Free Radical Biology & Medicine 20, no. 3 (1996): 463–466.

[79] B. Krümmel, A. S. von Hanstein, T. Plötz, S. Lenzen, and I. Mehmeti, “Differential Effects of Saturated and Unsaturated Free Fatty Acids on Ferroptosis in Rat β-Cells,” Journal of Nutritional Biochemistry 106 (2022): 109013.

[80] S. Wei, T. Qiu, X. Yao, et al., “Arsenic Induces Pancreatic Dysfunction and Ferroptosis via Mitochondrial ROS-Autophagy-Lysosomal Pathway,” Journal of Hazardous Materials 384 (2020): 121390.

[81] H. Hong, X. Lin, Y. Xu, et al., “Cadmium Induces Ferroptosis Mediated Inflammation by Activating Gpx4/Ager/p65 Axis in Pancreatic β-Cells,” Science of the Total Environment 849 (2022): 157819.

[82] D. Li, C. Jiang, G. Mei, et al., “Quercetin Alleviates Ferroptosis of Pancreatic β Cells in Type 2 Diabetes,” Nutrients 12, no. 10 (2020): 2954.

[83] M. C. Thomas, M. Brownlee, K. Susztak, et al., “Diabetic Kidney Disease,” Nature Reviews Disease Primers 1 (2015): 15018.

[84] W. M. McClellan, D. G. Warnock, S. Judd, et al., “Albuminuria and Racial Disparities in the Risk for ESRD,” Journal of the American Society of Nephrology 22, no. 9 (2011): 1721–1728.

[85] M. L. Merchant, M. T. Barati, D. J. Caster, et al., “Proteomic Analysis Identifies Distinct Glomerular Extracellular Matrix in Collapsing Focal Segmental Glomerulosclerosis,” Journal of the American Society of Nephrology 31, no. 8 (2020): 1883–1904.

[86] T. W. Tervaert, A. L. Mooyaart, K. Amann, et al., “Pathologic Classification of Diabetic Nephropathy,” Journal of the American Society of Nephrology 21, no. 4 (2010): 556–563.

[87] Q. Lei, X. Hou, X. Liu, et al., “Artificial Intelligence Assists Identification and Pathologic Classification of Glomerular Lesions in Patients With Diabetic Nephropathy,” Journal of Translational Medicine 22, no. 1 (2024): 397.

[88] M. E. Cooper, “Pathogenesis, Prevention, and Treatment of Diabetic Nephropathy,” Lancet 352, no. 9123 (1998): 213–219.

[89] K. E. Wellen and G. S. Hotamisligil, “Inflammation, Stress, and Diabetes,” Journal of Clinical Investigation 115, no. 5 (2005): 1111–1119.

[90] X. Ma, J. Ma, T. Leng, et al., “Advances in Oxidative Stress in Pathogenesis of Diabetic Kidney Disease and Efficacy of TCM Intervention,” Renal Failure 45, no. 1 (2023): 2146512.

[91] J. C. Jha, C. Banal, B. S. Chow, M. E. Cooper, and K. Jandeleit-Dahm, “Diabetes and Kidney Disease: Role of Oxidative Stress,” Antioxidants & Redox Signaling 25, no. 12 (2016): 657–684.

[92] S. Kim, S. W. Kang, J. Joo, et al., “Characterization of Ferroptosis in Kidney Tubular Cell Death Under Diabetic Conditions,” Cell Death & Disease 12, no. 2 (2021): 160.

[93] Y. Y. Qiao, J. L. Ji, W. L. Hou, et al., “tRF3-IleAAT Reduced Extracellular Matrix Synthesis in Diabetic Kidney Disease Mice by Targeting ZNF281 and Inhibiting Ferroptosis,” Acta Pharmacologica Sinica 45, no. 5 (2024): 1032–1043.

[94] Z. Liu, P. Nan, Y. Gong, L. Tian, Y. Zheng, and Z. Wu, “Endoplasmic Reticulum Stress-Triggered Ferroptosis via the XBP1-Hrd1-Nrf2 Pathway Induces EMT Progression in Diabetic Nephropathy,” Biomedicine & Pharmacotherapy 164 (2023): 114897.

[95] B. Huang, W. Wen, and S. Ye, “Dapagliflozin Ameliorates Renal Tubular Ferroptosis in Diabetes via SLC40A1 Stabilization,” Oxidative Medicine and Cellular Longevity 2022 (2022): 9735555.

[96] H. Q. Wang, H. X. Wu, W. Q. Shi, et al., “Triptolide Attenuates Renal Slit Diagram to Tight Junction Transition in Diabetic Kidney Disease by Regulating Nrf2-Ferroptosis Pathway,” American Journal of Chinese Medicine 52, no. 7 (2024): 2161–2185.

[97] H. Wang, X. Yu, D. Liu, et al., “VDR Activation Attenuates Renal Tubular Epithelial Cell Ferroptosis by Regulating Nrf2/HO-1 Signaling Pathway in Diabetic Nephropathy,” Advanced Science 11, no. 10 (2024): e2305563.

[98] R. Shen, X. Yu, C. Shi, Y. Fang, C. Dai, and Y. Zhou, “ACSL4 Predicts Rapid Kidney Function Decline in Patients With Diabetic Kidney Disease,” Frontiers in Endocrinology 16 (2025): 1499555.

[99] Y. H. Wang, D. Y. Chang, M. H. Zhao, and M. Chen, “Glutathione Peroxidase 4 Is a Predictor of Diabetic Kidney Disease Progression in Type 2 Diabetes Mellitus,” Oxidative Medicine and Cellular Longevity 2022 (2022): 2948248.

[100] X. Tang, X. Li, D. Zhang, and W. Han, “Astragaloside-IV Alleviates High Glucose-Induced Ferroptosis in Retinal Pigment Epithelial Cells by Disrupting the Expression of miR-138-5p/Sirt1/Nrf2,” Bioengineered 13, no. 4 (2022): 8240–8254.

[101] N. M. Alam, W. C. Mills, A. A. Wong, R. M. Douglas, H. H. Szeto, and G. T. Prusky, “A Mitochondrial Therapeutic Reverses Visual Decline in Mouse Models of Diabetes,” Disease Models & Mechanisms 8, no. 7 (2015): 701–710.

[102] Y. J. Chen, J. T. Chen, M. C. Tai, C. M. Liang, Y. Y. Chen, and W. L. Chen, “Serum Iron and Risk of Diabetic Retinopathy,” Nutrients 12, no. 8 (2020): 2297.

[103] Z. Fu, Z. Wang, C. H. Liu, et al., “Fibroblast Growth Factor 21 Protects Photoreceptor Function in Type 1 Diabetic Mice,” Diabetes 67, no. 5 (2018): 974–985.

[104] H. Bardak, A. C. Uğuz, Y. Bardak, J. Rocha-Pimienta, J. Delgado-Adámez, and J. Espino, “Selenium Protects ARPE-19 and ACBRI 181 Cells Against High Glucose-Induced Oxidative Stress,” Molecules 28, no. 16 (2023): 5961.

[105] J. Shao, Z. Bai, L. Zhang, and F. Zhang, “Ferrostatin-1 Alleviates Tissue and Cell Damage in Diabetic Retinopathy by Improving the Antioxidant Capacity of the Xc(−)-GPX4 System,” Cell Death Discovery 8, no. 1 (2022): 426.

[106] P. Malaviya, J. Kumar, and R. A. Kowluru, “Role of Ferroptosis in Mitochondrial Damage in Diabetic Retinopathy,” Free Radical Biology & Medicine 225 (2024): 821–832.

[107] J. Ouyang, L. Zhou, and Q. Wang, “Spotlight on Iron and Ferroptosis: Research Progress in Diabetic Retinopathy,” Frontiers in Endocrinology 14 (2023): 1234824.

[108] J. Zhang, Q. Qiu, H. Wang, C. Chen, and D. Luo, “TRIM46 Contributes to High Glucose-Induced Ferroptosis and Cell Growth Inhibition in Human Retinal Capillary Endothelial Cells by Facilitating GPX4 Ubiquitination,” Experimental Cell Research 407, no. 2 (2021): 112800.

[109] X. Fan, M. Xu, Q. Ren, et al., “Downregulation of Fatty Acid Binding Protein 4 Alleviates Lipid Peroxidation and Oxidative Stress in Diabetic Retinopathy by Regulating Peroxisome Proliferator-Activated Receptor γ-Mediated Ferroptosis,” Bioengineered 13, no. 4 (2022): 10540–10551.

[110] H. Zhou, L. Zhang, C. Ding, Y. Zhou, and Y. Li, “Upregulation of HMOX1 Associated With M2 Macrophage Infiltration and Ferroptosis in Proliferative Diabetic Retinopathy,” International Immunopharmacology 134 (2024): 112231.

[111] L. Mu, D. Wang, Z. Dong, et al., “Abnormal Levels of Serum Ferroptosis-Related Biomarkers in Diabetic Retinopathy,” Journal of Ophthalmology 2022 (2022): 3353740.

[112] D. Zheng, J. Liu, H. Piao, Z. Zhu, R. Wei, and K. Liu, “ROS-Triggered Endothelial Cell Death Mechanisms: Focus on Pyroptosis, Parthanatos, and Ferroptosis,” Frontiers in Immunology 13 (2022): 1039241.

[113] J. J. Park, “Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes,” Diabetes & Metabolism Journal 45, no. 2 (2021): 146–157.

[114] T. van de Weijer, V. B. Schrauwen-Hinderling, and P. Schrauwen, “Lipotoxicity in Type 2 Diabetic Cardiomyopathy,” Cardiovascular Research 92, no. 1 (2011): 10–18.

[115] X. Yan, Y. Xie, H. Liu, et al., “Iron Accumulation and Lipid Peroxidation: Implication of Ferroptosis in Diabetic Cardiomyopathy,” Diabetology and Metabolic Syndrome 15, no. 1 (2023): 161.

[116] Z. Chen, S. Li, M. Liu, et al., “Nicorandil Alleviates Cardiac Microvascular Ferroptosis in Diabetic Cardiomyopathy: Role of the Mitochondria-Localized AMPK-Parkin-ACSL4 Signaling Pathway,” Pharmacological Research 200 (2024): 107057.

[117] J. Zhen, X. Sheng, T. Chen, and H. Yu, “Histone Acetyltransferase Kat2a Regulates Ferroptosis via Enhancing Tfrc and Hmox1 Expression in Diabetic Cardiomyopathy,” Cell Death & Disease 15, no. 6 (2024): 406.

[118] A. F. Sampaio, M. Silva, W. C. Dornas, et al., “Iron Toxicity Mediated by Oxidative Stress Enhances Tissue Damage in an Animal Model of Diabetes,” Biometals 27, no. 2 (2014): 349–361.

[119] C. Zou, X. Liu, R. Xie, et al., “Deferiprone Attenuates Inflammation and Myocardial Fibrosis in Diabetic Cardiomyopathy Rats,” Biochemical and Biophysical Research Communications 486, no. 4 (2017): 930–936.

[120] S. Y. Wang, S. Zhu, J. Wu, et al., “Exercise Enhances Cardiac Function by Improving Mitochondrial Dysfunction and Maintaining Energy Homoeostasis in the Development of Diabetic Cardiomyopathy,” Journal of Molecular Medicine (Berlin, Germany) 98, no. 2 (2020): 245–261.

[121] N. S. Dhalla, P. K. Ganguly, S. K. Bhullar, and P. S. Tappia, “Role of Catecholamines in the Pathogenesis of Diabetic Cardiomyopathy (1),” Canadian Journal of Physiology and Pharmacology 97, no. 9 (2019): 815–819.

[122] S. A. Eid, A. E. Rumora, B. Beirowski, et al., “New Perspectives in Diabetic Neuropathy,” Neuron 111, no. 17 (2023): 2623–2641.

[123] G. Tang, L. Pi, H. Guo, et al., “Naringin Relieves Diabetic Cardiac Autonomic Neuropathy Mediated by P2Y(14) Receptor in Superior Cervical Ganglion,” Frontiers in Pharmacology 13 (2022): 873090.

[124] L. He, P. Huan, J. Xu, et al., “Hedysarum Polysaccharide Alleviates Oxidative Stress to Protect Against Diabetic Peripheral Neuropathy via Modulation of the keap1/Nrf2 Signaling Pathway,” Journal of Chemical Neuroanatomy 126 (2022): 102182.

[125] W. Lin, T. Zhang, J. Zheng, Y. Zhou, Z. Lin, and X. Fu, “Ferroptosis Is Involved in Hypoxic-Ischemic Brain Damage in Neonatal Rats,” Neuroscience 487 (2022): 131–142.

[126] R. J. Zeman, A. M. Brown, X. Wen, N. Ouyang, and J. D. Etlinger, “Tempol, a Superoxide Dismutase Mimetic, Inhibits Wallerian Degeneration Following Spinal Cord Injury by Preventing Glutathione Depletion and Aldose Reductase Activation,” Journal of Neurotrauma 41, no. 17–18 (2024): 2186–2198.

[127] S. J. Chen, J. Zhang, T. Zhou, et al., “Epigenetically Upregulated NSUN2 Confers Ferroptosis Resistance in Endometrial Cancer via m(5)C Modification of SLC7A11 mRNA,” Redox Biology 69 (2024): 102975.

[128] D. S. George, S. Hackelberg, N. D. Jayaraj, et al., “Mitochondrial Calcium Uniporter Deletion Prevents Painful Diabetic Neuropathy by Restoring Mitochondrial Morphology and Dynamics,” Pain 163, no. 3 (2022): 560–578.

[129] J. Zaugg, J. Lopez-Tello, B. Musial, et al., “Obesogenic Diet in Pregnancy Disrupts Placental Iron Handling and Ferroptosis and Stress Signalling in Association With Fetal Growth Alterations,” Cellular and Molecular Life Sciences 81, no. 1 (2024): 151.

[130] S. M. Won, J. H. Lee, U. J. Park, J. Gwag, B. J. Gwag, and Y. B. Lee, “Iron Mediates Endothelial Cell Damage and Blood-Brain Barrier Opening in the Hippocampus After Transient Forebrain Ischemia in Rats,” Experimental & Molecular Medicine 43, no. 2 (2011): 121–128.

[131] D. Vela, “Hepcidin, an Emerging and Important Player in Brain Iron Homeostasis,” Journal of Translational Medicine 16, no. 1 (2018): 25.

[132] P. Hong, R. N. Gu, F. X. Li, et al., “NLRP3 Inflammasome as a Potential Treatment in Ischemic Stroke Concomitant With Diabetes,” Journal of Neuroinflammation 16, no. 1 (2019): 121.

[133] Z. Xie, X. Wang, X. Luo, et al., “Activated AMPK Mitigates Diabetes-Related Cognitive Dysfunction by Inhibiting Hippocampal Ferroptosis,” Biochemical Pharmacology 207 (2023): 115374.

[134] J. J. van Netten, S. A. Bus, J. Apelqvist, et al., “Definitions and Criteria for Diabetic Foot Disease,” Diabetes/Metabolism Research and Reviews 36, no. Suppl 1 (2020): e3268.

[135] J. Feng, J. Wang, Y. Wang, et al., “Oxidative Stress and Lipid Peroxidation: Prospective Associations Between Ferroptosis and Delayed Wound Healing in Diabetic Ulcers,” Frontiers in Cell and Developmental Biology 10 (2022): 898657.

[136] J. Chen, X. Li, H. Liu, et al., “Bone Marrow Stromal Cell-Derived Exosomal Circular RNA Improves Diabetic Foot Ulcer Wound Healing by Activating the Nuclear Factor Erythroid 2-Related Factor 2 Pathway and Inhibiting Ferroptosis,” Diabetic Medicine 40, no. 7 (2023): e15031.

[137] S. Li, Y. Li, Z. Wu, Z. Wu, and H. Fang, “Diabetic Ferroptosis Plays an Important Role in Triggering on Inflammation in Diabetic Wound,” American Journal of Physiology. Endocrinology and Metabolism 321, no. 4 (2021): E509–e520.

[138] F. Villa, H. Marchandin, J. P. Lavigne, et al., “Anaerobes in Diabetic Foot Infections: Pathophysiology, Epidemiology, Virulence, and Management,” Clinical Microbiology Reviews 37, no. 3 (2024): e0014323.

[139] L. Deng, G. Wang, and S. Ju, “Correlation Between Inflammatory Factors, Autophagy Protein Levels, and Infection in Granulation Tissue of Diabetic Foot Ulcer,” Immunity, Inflammation and Disease 12, no. 4 (2024): e1233.

[140] Q. Han, Y. Gu, and Y. Qian, “Study on the Mechanism of Activating SIRT1/Nrf2/p62 Pathway to Mediate Autophagy-Dependent Ferroptosis to Promote Healing of Diabetic Foot Ulcers,” Naunyn-Schmiedeberg's Archives of Pharmacology 398, no. 3 (2025): 3015–3025.

[141] Y. B. Wang, Z. P. Li, P. Wang, et al., “Iron Dysregulation, Ferroptosis, and Oxidative Stress in Diabetic Osteoporosis: Mechanisms, Bone Metabolism Disruption, and Therapeutic Strategies,” World Journal of Diabetes 16, no. 6 (2025): 106720.

[142] T. Gan, Q. Wang, Y. Song, et al., “Canagliflozin Improves Fatty Acid Oxidation and Ferroptosis of Renal Tubular Epithelial Cells via FOXA1-CPT1A Axis in Diabetic Kidney Disease,” Molecular and Cellular Endocrinology 582 (2024): 112139.

[143] S. Du, H. Shi, L. Xiong, P. Wang, and Y. Shi, “Canagliflozin Mitigates Ferroptosis and Improves Myocardial Oxidative Stress in Mice With Diabetic Cardiomyopathy,” Frontiers in Endocrinology 13 (2022): 1011669.

[144] H. Asil, A. T. Demiryürek, I. V. Düzen, et al., “Effects of Empagliflozin and Dapagliflozin on Serum Humanin, MOTS-c Levels, Nitrosative Stress, and Ferroptosis Parameters in Diabetic Patients With Heart Failure,” European Journal of Pharmacology 982 (2024): 176934.

[145] L. Xi, J. Du, Y. Lu, et al., “Dulaglutide Accelerates Diabetic Wound Healing by Suppressing Nrf2-Dependent Ferroptosis in Diabetic Mice,” Peptides 185 (2025): 171366.

[146] X. Chen, T. Wang, Y. Gao, G. A. Wang, J. Guan, and H. Dai, “Liraglutide Suppresses Ferroptosis by Upregulation NRF2 in Type 2 Diabetic Cardiomyopathy,” Peptides 192 (2025): 171429.

[147] J. R. An, J. N. Su, G. Y. Sun, et al., “Liraglutide Alleviates Cognitive Deficit in Db/Db Mice: Involvement in Oxidative Stress, Iron Overload, and Ferroptosis,” Neurochemical Research 47, no. 2 (2022): 279–294.

[148] S. Tian, S. Zhou, W. Wu, et al., “GLP-1 Receptor Agonists Alleviate Diabetic Kidney Injury via β-Klotho-Mediated Ferroptosis Inhibition,” Advanced Science 12, no. 4 (2025): e2409781.

[149] Y. Ding and Q. Wu, “1,25D/VDR Inhibits Pancreatic β Cell Ferroptosis by Downregulating FOXO1 Expression in Diabetes Mellitus,” Cellular Signalling 105 (2023): 110564.

[150] M. Wang, Y. Liu, H. Gui, et al., “ED-71 Ameliorates Bone Regeneration in Type 2 Diabetes by Reducing Ferroptosis in Osteoblasts via the HIF1α Pathway,” European Journal of Pharmacology 969 (2024): 176303.

[151] D. Zhan, J. Zhao, Q. Shi, J. Lou, and W. Wang, “25-Hydroxyvitamin D3 Inhibits Oxidative Stress and Ferroptosis in Retinal Microvascular Endothelial Cells Induced by High Glucose Through Down-Regulation of miR-93,” BMC Ophthalmology 23, no. 1 (2023): 22.

[152] S. Li, L. Zheng, J. Zhang, X. Liu, and Z. Wu, “Inhibition of Ferroptosis by Up-Regulating Nrf2 Delayed the Progression of Diabetic Nephropathy,” Free Radical Biology & Medicine 162 (2021): 435–449.

[153] S. Chen, X. Wang, D. Sun, et al., “Fenofibrate Exerts Protective Effects in Diabetic Retinopathy,” Current Eye Research 50 (2025): 1–9.

[154] Z. Wu, D. Li, D. Tian, X. Liu, and Z. Wu, “Aspirin Mediates Protection From Diabetic Kidney Disease by Inducing Ferroptosis Inhibition,” PLoS One 17, no. 12 (2022): e0279010.

[155] Y. Zhang, Y. Qu, R. Cai, et al., “Atorvastatin Ameliorates Diabetic Nephropathy Through Inhibiting Oxidative Stress and Ferroptosis Signaling,” European Journal of Pharmacology 976 (2024): 176699.

[156] Z. Wei, Q. Shaohuan, K. Pinfang, and S. Chao, “Curcumin Attenuates Ferroptosis-Induced Myocardial Injury in Diabetic Cardiomyopathy Through the Nrf2 Pathway,” Cardiovascular Therapeutics 2022 (2022): 3159717.

[157] T. Kose, M. Vera-Aviles, P. A. Sharp, and G. O. Latunde-Dada, “Curcumin and (−)- Epigallocatechin-3-Gallate Protect Murine MIN6 Pancreatic Beta-Cells Against Iron Toxicity and Erastin-Induced Ferroptosis,” Pharmaceuticals (Basel) 12, no. 1 (2019): 26.

[158] K. Gao, Y. Liu, K. Li, et al., “Nrf2-Mediated Ferroptosis Is Involved in Berberine-Induced Alleviation of Diabetic Kidney Disease,” Phytotherapy Research 39 (2025): 5604–5616.

[159] T. Jin and C. Chen, “Umbelliferone Delays the Progression of Diabetic Nephropathy by Inhibiting Ferroptosis Through Activation of the Nrf-2/HO-1 Pathway,” Food and Chemical Toxicology 163 (2022): 112892.

[160] D. Huang, P. Shen, C. Wang, J. Gao, C. Ye, and F. Wu, “Calycosin Plays a Protective Role in Diabetic Kidney Disease Through the Regulation of Ferroptosis,” Pharmaceutical Biology 60, no. 1 (2022): 990–996.

[161] J. Chen, Z. Ou, T. Gao, et al., “Ginkgolide B Alleviates Oxidative Stress and Ferroptosis by Inhibiting GPX4 Ubiquitination to Improve Diabetic Nephropathy,” Biomedicine & Pharmacotherapy 156 (2022): 113953.

[162] J. Jia, R. Tan, L. Xu, et al., “Hederagenin Improves Renal Fibrosis in Diabetic Nephropathy by Regulating Smad3/NOX4/SLC7A11 Signaling-Mediated Tubular Cell Ferroptosis,” International Immunopharmacology 135 (2024): 112303.

[163] Y. Liu, Y. Cai, X. Wei, et al., “Molecular Mechanisms of Potentilla Discolor Bunge in Regulating Ferroptosis to Alleviate DKD via the Nrf2 Signaling Pathway,” Journal of Ethnopharmacology 350 (2025): 120035.

[164] X. M. Shan, C. Lu, C. W. Chen, et al., “Tangshenning Formula Alleviates Tubular Injury in Diabetic Kidney Disease via the Sestrin2/AMPK/PGC-1α Axis: Restoration of Mitochondrial Function and Inhibition of Ferroptosis,” Journal of Ethnopharmacology 345 (2025): 119579.

[165] R. Yang, W. Liu, Y. Zhou, et al., “Modulating HIF-1α/HIF-2α Homeostasis With Shen-Qi-Huo-Xue Formula Alleviates Tubular Ferroptosis and Epithelial-Mesenchymal Transition in Diabetic Kidney Disease,” Journal of Ethnopharmacology 343 (2025): 119478.

[166] H. Ma, X. Wang, W. Zhang, et al., “Melatonin Suppresses Ferroptosis Induced by High Glucose via Activation of the Nrf2/HO-1 Signaling Pathway in Type 2 Diabetic Osteoporosis,” Oxidative Medicine and Cellular Longevity 2020 (2020): 9067610.

[167] X. Wang, X. Chen, W. Zhou, et al., “Ferroptosis Is Essential for Diabetic Cardiomyopathy and Is Prevented by Sulforaphane via AMPK/NRF2 Pathways,” Acta Pharmaceutica Sinica B 12, no. 2 (2022): 708–722.

[168] F. Zhang, Z. Zeng, J. Zhang, et al., “Pterostilbene Attenuates Heart Failure by Inhibiting Myocardial Ferroptosis Through SIRT1/GSK-3β/GPX4 Signaling Pathway,” Heliyon 10, no. 3 (2024): e24562.

[169] X. Tian, L. Ruan, S. Zhou, et al., “Appropriate Size of Fe(3)O(4) Nanoparticles for Cancer Therapy by Ferroptosis,” ACS Applied Bio Materials 5, no. 4 (2022): 1692–1699.

[170] N. Xiao, S. Xiong, Z. Zhou, et al., “Recent Progress in Biomaterials-Driven Ferroptosis for Cancer Therapy,” Biomaterials Science 12, no. 2 (2024): 288–307.

[171] X. Chen, C. Yu, R. Kang, G. Kroemer, and D. Tang, “Cellular Degradation Systems in Ferroptosis,” Cell Death and Differentiation 28, no. 4 (2021): 1135–1148.

RIGHTS & PERMISSIONS

2026 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.